Search results
New weight loss drugs are coming, and they could burn more fat with fewer side effects
NBC News via Yahoo News· 2 days agoThere aren’t just GLP-1 drugs in the pipeline. On Thursday, ahead of the diabetes conference,...
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Reuters· 4 days agoAmylyx Pharmaceuticals has agreed to buy the rights to bankrupt drugmaker Eiger BioPharmaceuticals' ...
New drug’s potentially fatal side effects obscured by ‘soothing acronym,’ doctors say
The Columbian· 2 days agoSeventy-nine-year-old Genevieve Lane volunteered to take the Alzheimer’s drug Leqembi in a clinical trial because she was forgetting words and misplacing her keys. Infusions ...
New weight loss drugs are on the way — and the health benefits are even more promising
The Independent via Yahoo News· 1 day agoAltimmune expects to begin a phase three trial soon. The company hopes the drug will be available in...
Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval
Investor's Business Daily· 24 hours agoChico noted 99% of patients in the Adhere test also enrolled in an open-label extension study. In an...
Wave, with new data, plots path forward for Huntington’s drug
BioPharma Dive via Yahoo Finance· 8 hours agoThe company plans to make a case to regulators for a new accelerated approval pathway. But investors...
Merck KGgA shares slide after failure of potential head and neck cancer drug
Investing.com via Yahoo Finance· 14 hours agoInvesting.com -- Shares in Merck KGaA (ETR:MRCG) slumped by more than 10% on Tuesday after the drugmaker announced that it had discontinued a Phase III study evaluating its treatment for patients with head and neck cancer.
Zealand Offers $900 Million in Shares to Fund New Obesity Drugs
Bloomberg via Yahoo Finance· 4 hours ago(Bloomberg) -- Zealand Pharma A/S is selling about 6.3 billion Danish kroner ($900 million) in new...
Jazz Pharmaceuticals' tremor drug fails in mid-stage study
Reuters via Yahoo News· 5 days ago(Reuters) -Jazz Pharmaceuticals said on Thursday its experimental drug to treat a common movement disorder failed to reduce tremor severity in a mid-stage ...
Forget Eli Lilly, Buy This Magnificent Biotech Stock Instead
Motley Fool via Yahoo Finance· 4 days agoThis deal will add povetacicept to Vertex's portfolio. The experimental drug has shown promise in...